---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-019747"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T15:57:53.054067+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics signs collaboration with Abbott to support Phase 3 LVAD trial of tecarfarin

## Summary
- Abbott will share LVAD data from MOMENTUM 3 and ARIES HM3 trials for TECH-LVAD trial design.
- Abbott to assist with biostatistics, site selection, patient enrollment, and medical science liaison.
- Cadrenal is regulatory sponsor; tecarfarin-related IP owned by Cadrenal, device-related IP by Abbott.
- Phase 3 TECH-LVAD trial compares tecarfarin vs warfarin in HeartMate 3 LVAD patients with open-label extension.
- No upfront or milestone payments disclosed; Cadrenal still pursuing additional funding partnerships for the study.

## SEC filing metadata
- accession: 0001213900-25-019747
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390025019747/0001213900-25-019747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390025019747/ea0231833-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-019747
- JSON: https://secwatch.observer/filing/0001213900-25-019747.json
- Plain text: https://secwatch.observer/filing/0001213900-25-019747.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.